Immunomedics, Inc. (IMMU - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $1.15 to $1.31 in the past one month time frame.
The move came after the company revealed news about its cancer asset IMMU-132 at yesterday's annual San Antonio Breast Cancer Symposium that showed overall survival (OS) has since stumbled from data seen in January.
The company has seen one negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Immunomedics, Inc. Price
A better-ranked stock in the Medical sector is Myriad Genetics, Inc. (MYGN - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is IMMU going up? Or down? Predict to see what others think: Up or Down.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>